Ajax Therapeutics

Ajax is pursuing uniquely selective approaches to develop novel next generation therapies for hematologic cancers, including myeloproliferative neoplasms (MPNs). By combining the deep cancer and structural biology insights of our founding scientists with the industry’s most advanced computational drug discovery and protein structure platforms, we aim to discover and develop more precisely designed therapies to address the significant unmet needs for patients with MPNs, including myelofibrosis, which are driven by aberrant JAK/STAT signaling due to mutations in JAK2, MPL and CALR genes. Our focus is developing next-generation JAK2 inhibitors that address the significant unmet needs of patients with myelofibrosis (MF) including the treatment of patients who are resistant or refractory to existing JAK2 therapies and providing disease modifying effects. Ajax’s lead clinical candidate, AJ1-11095, is the first Type II JAK2 inhibitor to enter the clinic. Type II JAK2 inhibitors have been shown to improve therapeutic efficacy, overcome disease persistence to Type I JAK2 inhibitors, including ruxolitinib, and, most importantly, reduce mutant JAK2 allele burden that drives MPNs. AJ1-11095 is currently in a Phase I study in the US for patients who have been failed by a Type I JAK2 inhibitor.